Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?

Uludag, Omer; Cinar, Suzan; McDonnell, Thomas; Çene, Erhan; yalcinkaya, yasemin; Gül, Ahmet; Inanc, Murat; Artım Esen, Bahar

doi:10.55730/1300-0144.5671

Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?

Ömer ULUDAĞ, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Anabilim Dalı, İstanbul, Türkiye)

Suzan ÇINAR, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, İmmünoloji Anabilim Dalı, İstanbul, Türkiye)

Thomas MCDONNELL, (Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom)

Erhan ÇENE, (Yıldız Teknik Üniversitesi, Fen Edebiyat Fakültesi, İstatistik Bölümü, İstanbul, Türkiye)

Yasemin YALÇINKAYA, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Anabilim Dalı, İstanbul, Türkiye)

Ahmet GÜL, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Anabilim Dalı, İstanbul, Türkiye)

Murat İNANÇ, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Anabilim Dalı, İstanbul, Türkiye)

Bahar ARTIM ESEN (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Anabilim Dalı, İstanbul, Türkiye)

Turkish Journal of Medical Sciences

2 0

Yıl: 2023 Cilt: 53 Sayı: 5 Sayfa Aralığı: 1067 - 1074 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5671 İndeks Tarihi: 24-11-2023

Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?

Öz:

Background/aim: In this cross-sectional study, it was aimed to test the predictive value of noncriteria antiphospholipid antibodies (aPL) in addition to the global antiphospholipid syndrome score (GAPSS) in predicting vascular thrombosis (VT) in a cohort of patients with APS and aPL (+) systemic lupus erythematosus (SLE). Material and methods: This study included 50 patients with primary APS, 68 with SLE/APS, and 52 with aPL (+) SLE who were classified according to VT as VT ± pregnancy morbidity (PM), PM only or aPL (+) SLE. Antiphospholipid serology consisting of lupus anticoagulant (LA), anticardiolipin (aCL) immunoglobulin G (IgG)/IgM/IgA, antibeta2 glycoprotein I (aβ2GPI) IgG/IgM/IgA, antiphosphatidylserine/prothrombin (aPS/PT) IgG/IgM and antidomain-I (aDI) IgG was determined for each patient. The GAPSS and adjusted GAPSS (aGAPSS) were calculated for each patient, as previously defined. Logistic regression analysis was carried out with thrombosis as the dependent variable and high GAPSS, aCL IgA, aβ2GPI IgA, and aDI IgG as independent variables. Results: The mean GAPSS and aGAPSS of the study population were 11.6 ± 4.4 and 9.6 ± 3.8. Both the VT ± PM APS (n = 105) and PM only APS (n = 13) groups had significantly higher GAPSS and aGAPSS values compared to the aPL (+) SLE (n = 52) group. The patients with recurrent thrombosis had higher aGAPSS but not GAPSS than those with a single thrombotic event. The computed area under the receiver operating characteristic curve demonstrated that a GAPSS ≥13 and aGAPSS ≥10 had the best predictive values for thrombosis. Logistic regression analysis including a GAPSS ≥13, aCL IgA, aβ2GPI IgA, and aDI IgG showed that none of the factors other than a GAPSS ≥13 could predict thrombosis. Conclusion: Both the GAPSS and aGAPSS successfully predict the thrombotic risk in aPL (+) patients and aCL IgA, aβ2GPI IgA, and aDI IgG do not contribute to high a GAPSS or aGAPSS.

Anahtar Kelime: Antiphospholipid syndrome global antiphospholipid syndrome score thrombotic risk non-criteria antiphospholipid antibodies

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis 2006; 4 (2): 295-306. https://doi.org/10.1111/j.1538-7836.2006.01753.x
2. Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Annals of the Rheumatic Diseases 2015; 74 (6): 1011-1018. https://doi. org/10.1136/annrheumdis-2013-204838
3. Ruffatti A, Del Ross T, Ciprian M, Bertero MT, Sciascia S et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Annals of the Rheumatic Diseases 2011; 70 (6): 1083-1086. https://doi.org/10.1136/ard.2010.142042
4. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thrombosis and Haemostasis 2005; 93 (6): 1147- 1152. https://doi.org/10.1160/th04-12-0839
5. Žigon P, Podovšovnik A, Ambrožič A, Tomšič M, Hočevar A et al. Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements. Clinical Rheumatology 2019; 38 (2): 371-378. https://doi.org/10.1007/s10067-018-4251-7
6. Shi H, Zheng H, Yin YF, Hu QY, Teng JL et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. Clinical Chemistry and Laboratory Medicine 2018; 56 (4): 614-624. https://doi.org/10.1515/cclm-2017-0502
7. de Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. Journal of Thrombosis and Haemostasis 2009; 7 (11): 1767-1773. https://doi.org/10.1111/j.1538- 7836.2009.03588.x
8. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA et al. GAPSS: the global anti-phospholipid syndrome score. Rheumatology (Oxford) 2013; 52 (8):1397-1403. https://doi. org/10.1093/rheumatology/kes388
9. Otomo K, Atsumi T, Amengual O, Fujieda Y, Kato M et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis and Rheumatism 2012; 64 (2): 504-512. https://doi.org/10.1002/art.33340
10. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA et al. The global anti-phospholipid syndrome score in primary APS. Rheumatology 2015; 54 (1): 134-138. https://doi. org/10.1093/rheumatology/keu307
11. Barilaro G, Esteves A, Della Rocca C, Perez-Isidro A, Araujo O et al. Predictive value of the Adjusted Global Anti-Phospholipid Syndrome Score on clinical recurrence in APS patients: a longitudinal study. Rheumatology 2023; 62 (4): 1576-1585. https://doi.org/10.1093/rheumatology/keac485
12. Garcia L, Velloso MS, Martire MV, Savy F, Arizpe F et al. Validation of the adjusted global antiphospholipid syndrome score in systemic lupus erythematosus patients in Argentina. Lupus 2020; 29 (14): 1866-1872. https://doi. org/10.1177/0961203320960814
13. Fernandez Mosteirin N, Saez Comet L, Salvador Osuna C, Calvo Villas JM, Velilla Marco J. Independent validation of the adjusted GAPSS: role of thrombotic risk assessment in the real-life setting. Lupus 2017; 26 (12): 1328-1332. https://doi. org/10.1177/0961203317703493
14. Oku K, Amengual O, Bohgaki T, Horita T, Yasuda S et al. An independent validation of the global anti-phospholipid syndrome score in a Japanese cohort of patients with autoimmune diseases. Lupus 2015; 24 (7): 774-775. https://doi. org/10.1177/0961203314561284
15. Uludağ Ö, Bektaş M, Çene E, Sezer M, Şahinkaya Y et al. Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey. Journal of Thrombosis and Thrombolysis 2021; 51 (2): 466-474. https://doi.org/10.1007/s11239-020-02195-4
16. Nascimento IS, Radin M, Gândara APR, Sciascia S, de Andrade DCO. Global antiphospholipid syndrome score and anti-ß2-glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: a four-year prospective study. Lupus 2020; 29 (7): 676-685. https://doi. org/10.1177/0961203320916527
17. Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou MG et al. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort. Seminars in Arthritis and Rheumatism 2019; 49 (3): 464-468. https://doi.org/10.1016/j. semarthrit.2019.04.009
18. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism 2012; 64 (8): 2677- 2686. https://doi.org/10.1002/art.34473
19. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal 2018; 39 (33): 3021- 3104. https://doi.org/10.1093/eurheartj/ehy339
20. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/ APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology 2019; 73 (24): e285-e350. https://doi.org/10.1016/j. jacc.2018.11.003
21. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care 2020; 43 (1): S14-S31. https://doi.org/10.2337/dc20-s002
22. Pengo V. ISTH guidelines on lupus anticoagulant testing. Thrombosis Research 2012; 130 (1): S76-77. https://doi. org/10.1016/j.thromres.2012.08.283
23. Pericleous C, Ferreira I, Borghi O, Pregnolato F, McDonnell T et al. Measuring IgA anti-β2-glycoprotein I and IgG/IgA anti- domain I antibodies adds value to current serological assays for the antiphospholipid syndrome. PloS One 2016; 11 (6): e0156407. https://doi.org/10.1371/journal.pone.0156407
24. Sciascia S, Cosseddu D, Montaruli B, Kuzenko A, Bertero MT. Risk Scale for the diagnosis of antiphospholipid syndrome. Annals of the Rheumatic Diseases 2011; 70 (8): 1517-1578. https://doi.org/10.1136/ard.2010.145177
25. Ruffatti A, Del Ross T, Ciprian M, Nuzzo M, Rampudda M et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Annals of the Rheumatic Diseases 2009; 68 (3): 397-399. https:// doi.org/10.1136/ard.2008.096669
26. Demir S, Li J, Magder LS, Petri M. Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus. Rheumatology 2021; 60 (8): 3770-3777. https://doi.org/10.1093/ rheumatology/keaa857
27. Sciascia S, Radin M, Sanna G, Cecchi I, Roccatello D et al. Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis. Rheumatology 2018; 57 (4): 661-665. https://doi.org/10.1093/rheumatology/kex466
28. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA et al. Anti-prothrombin (aPT) and anti-phosphatidylserine/ prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thrombosis and Haemostasis 2014; 111 (2): 354-364. https:// doi.org/10.1160/th13-06-0509
29. Andreoli L, Fredi M, Nalli C, Piantoni S, Reggia R et al. Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies. Current Rheumatology Reports 2013; 15 (7): 343. https://doi.org/10.1007/s11926-013-0343-1
30. De Craemer AS, Musial J, Devreese KM. Role of anti- domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. Journal of Thrombosis and Haemostasis 2016; 14 (9): 1779-1787. https:// doi.org/10.1111/jth.13389

APA	Uludag O, Cinar S, McDonnell T, Çene E, yalcinkaya y, Gül A, Inanc M, Artım Esen B (2023). Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?. , 1067 - 1074. 10.55730/1300-0144.5671
Chicago	Uludag Omer,Cinar Suzan,McDonnell Thomas,Çene Erhan,yalcinkaya yasemin,Gül Ahmet,Inanc Murat,Artım Esen Bahar Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?. (2023): 1067 - 1074. 10.55730/1300-0144.5671
MLA	Uludag Omer,Cinar Suzan,McDonnell Thomas,Çene Erhan,yalcinkaya yasemin,Gül Ahmet,Inanc Murat,Artım Esen Bahar Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?. , 2023, ss.1067 - 1074. 10.55730/1300-0144.5671
AMA	Uludag O,Cinar S,McDonnell T,Çene E,yalcinkaya y,Gül A,Inanc M,Artım Esen B Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?. . 2023; 1067 - 1074. 10.55730/1300-0144.5671
Vancouver	Uludag O,Cinar S,McDonnell T,Çene E,yalcinkaya y,Gül A,Inanc M,Artım Esen B Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?. . 2023; 1067 - 1074. 10.55730/1300-0144.5671
IEEE	Uludag O,Cinar S,McDonnell T,Çene E,yalcinkaya y,Gül A,Inanc M,Artım Esen B "Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?." , ss.1067 - 1074, 2023. 10.55730/1300-0144.5671
ISNAD	Uludag, Omer vd. "Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?". (2023), 1067-1074. https://doi.org/10.55730/1300-0144.5671

APA	Uludag O, Cinar S, McDonnell T, Çene E, yalcinkaya y, Gül A, Inanc M, Artım Esen B (2023). Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?. Turkish Journal of Medical Sciences, 53(5), 1067 - 1074. 10.55730/1300-0144.5671
Chicago	Uludag Omer,Cinar Suzan,McDonnell Thomas,Çene Erhan,yalcinkaya yasemin,Gül Ahmet,Inanc Murat,Artım Esen Bahar Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?. Turkish Journal of Medical Sciences 53, no.5 (2023): 1067 - 1074. 10.55730/1300-0144.5671
MLA	Uludag Omer,Cinar Suzan,McDonnell Thomas,Çene Erhan,yalcinkaya yasemin,Gül Ahmet,Inanc Murat,Artım Esen Bahar Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?. Turkish Journal of Medical Sciences, vol.53, no.5, 2023, ss.1067 - 1074. 10.55730/1300-0144.5671
AMA	Uludag O,Cinar S,McDonnell T,Çene E,yalcinkaya y,Gül A,Inanc M,Artım Esen B Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?. Turkish Journal of Medical Sciences. 2023; 53(5): 1067 - 1074. 10.55730/1300-0144.5671
Vancouver	Uludag O,Cinar S,McDonnell T,Çene E,yalcinkaya y,Gül A,Inanc M,Artım Esen B Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?. Turkish Journal of Medical Sciences. 2023; 53(5): 1067 - 1074. 10.55730/1300-0144.5671
IEEE	Uludag O,Cinar S,McDonnell T,Çene E,yalcinkaya y,Gül A,Inanc M,Artım Esen B "Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?." Turkish Journal of Medical Sciences, 53, ss.1067 - 1074, 2023. 10.55730/1300-0144.5671
ISNAD	Uludag, Omer vd. "Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?". Turkish Journal of Medical Sciences 53/5 (2023), 1067-1074. https://doi.org/10.55730/1300-0144.5671